Pebruari 02, 2018

Phapros Won E-Catalogue Tender Worth Rp 2 Trillion

JAKARTA - PT Phapros, Tbk which is also one of subsidiaries of PT RNI (Persero) has won the e-catalogue drugs tender for 2018 to 2019.

“In 2018, the values of e-catalogue won by Phapros rose significantly from the total value we got in 2017, where the last year’s value was as much as Rp 498 billion,” President Director of Phapros, Barokah Sri Utami stated.

In the future, Phapros will ensure that the supply remains good, So Phapros can give the best contribution on BPJS Program.

According to Emmy, the opportunity for Phapros entering e-catalogue market is getting bigger from year to year. In 2013, the value of government’s budget on e-catalogue market in the health sector reached more than Rp 4 trillion, and this number has increased in 2017 to 2018 which reached Rp 9 trillion. So, this is what encourages Phapros to give a positive contribution in the era of National Health Insurance.

According to the announcement announced by LKPP in the end of 2017, Phapros has on the e-catalogue tender for 2018 to 2019 worth Rp 2 triliion. There are 27 types of generic drug packages that Phapros won, where the amount is still beyond the 9 types of additional generic drug packages worth more than Rp 40 billion. Thus, the total drugs Phapros won are as many as 36 types.

Among those 36 types of product, blood enhancing tablet and fixed-dose combination (FDC) are the biggest sales contributors which the value is up to Rp 300 billion.

“FDC and blood enhancing tablet is the government’s program. We know that currently our government is trying to reduce the number of stunted children and tuberculosis that remain high in Indonesia, so we hope that by winning FDC and blood enhancing tablet through e-catalogue, we can strengthen our commitment to contribute in overcoming those two main problems in the health sector,” Emmy said.

Phapros, according to Emmy, has strength in TB drug products (tuberculosis) and blood enhancing tablet. The optimization of production capacity funded by MTN issuance is also directed to the production of both types of drugs.